文献速递膀胱癌与上尿路尿路上皮癌

研究膀胱癌尿液标志物的最佳试验设计:协作综述

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

该协作综述通过PubMed检索(2018年2月17日)发现,尿液标志物因缺乏临床获益的明确证据而未常规用于膀胱癌诊断和监测。作者针对血尿人群检测和膀胱癌人群监测提出了多种试验设计,认为基于标志物的策略可能减少低风险患者不必要的膀胱镜检查并加速高风险患者诊疗。

要点

  • 尿液标志物目前未常规用于膀胱癌诊疗,因缺乏支持其纳入诊疗流程的1级证据。
  • 针对血尿评估,基于标志物的策略可能减少低风险患者膀胱镜检并加速高风险患者诊疗。
  • 针对膀胱癌监测,基于标志物的策略可能减少低级别病变患者的膀胱镜检并可能改善高风险患者的检测。

核心结论

  • 尿液标志物目前未常规用于膀胱癌检测或监测,因缺乏支持其纳入诊疗流程的1级证据。
  • 本综述提供了可证明基于标志物策略优于当前临床诊疗的实用研究设计。
  • 这些研究所需样本量不大于既往尿液标志物研究,但所提试验概念需要规划和承担标志物未能显示预期获益风险的意愿。

研究设计与样本

  • 协作综述,于2018年2月17日进行PubMed检索。
  • 检索词「Urinary Bladder Neoplasms」[Mesh] AND「Biomarkers」[Mesh] AND「Urine」[Mesh]共获得127篇文章,其中仅2篇同时符合「Randomized Controlled Trial」[Publication Type]。
  • 上述2篇文章均未考察患者临床结局,而是聚焦于尿液标志物的性能特征。
  • 检索词「Hematuria」[Mesh] AND「Randomized Controlled Trial」[Publication Type] AND「Urinary Bladder Neoplasms」[Mesh]共获得12篇文章,均未采用以临床终点为结局的随机化设计。

主要发现

  • 在初级保健机构血尿评估中,与常规诊疗相比,基于标志物的策略可能减少低风险患者不必要的膀胱镜检查并加速高风险患者的诊疗。
  • 在膀胱癌监测中,基于标志物的策略可能减少低级别病变患者的膀胱镜检查并可能改善高风险患者的检测。
  • 针对检测和监测,已开发出多种潜在的尿液标志物试验设计。

关键数值与推荐

  • 尿液标志物目前未常规使用,因缺乏支持将其纳入膀胱癌检测或监测方案的1级证据。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,本综述提供了可证明基于标志物策略优于当前临床诊疗的实用研究设计。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Urine-based tumor markers are not routinely used in the diagnosis and surveillance of bladder cancer. The main limitation of urinary markers has been a lack of clarity regarding clinical benefit. OBJECTIVE: To review the indications for urinary marker use, barriers to marker utilization, and clinical trial designs for markers available for detection (hematuria populations) and surveillance (bladder cancer populations). The study aim was to facilitate an optimal trial design that could change clinical practice. EVIDENCE ACQUISITION: A PubMed search was conducted on February 17, 2018, using the MeSH search terms "Urinary Bladder Neoplasms" [Mesh] AND "Biomarkers" [Mesh] AND "Urine" [Mesh] yielded 127 articles, of which only two also fulfilled the search term "Randomized Controlled Trial" [Publication Type]. Neither of these two articles examined clinical outcomes for patients but rather focused on the performance characteristics of the urinary marker. For the search terms "Hematuria" [Mesh] AND "Randomized Controlled Trial" [Publication Type] AND "Urinary Bladder Neoplasms" [Mesh] yielded 12 articles, none of which used randomization with the outcome of interest being a clinical endpoint. EVIDENCE SYNTHESIS: Several potential designs for urinary marker trials were developed for detection and surveillance of bladder cancer. A marker-based approach compared to usual care for evaluation of hematuria in a primary care setting could reduce unnecessary cystoscopy in patients with low risk and expedite care in patients with higher risk. For bladder cancer surveillance, marker-based approaches could reduce cystoscopy for patients with low-grade disease and potentially improve detection for patients with high risk. CONCLUSIONS: Urinary markers are not currently routinely used owing to the absence of level 1 evidence supporting incorporation of urinary markers into protocols for detection or surveillance of bladder cancer. This review provides practical designs for studies that could demonstrate superiority of marker-based approaches over current clinical care. The sample sizes required for these studies are no greater than many of those accrued for previous urinary marker studies, but the proposed trial concepts require planning and a willingness to risk failure of the marker to demonstrate the desired benefits. PATIENT SUMMARY: In this review we discuss current limitations in the use of urinary markers for detection and surveillance of bladder cancer. We identify potential studies that could demonstrate a clinical benefit of the use of markers in improving detection of bladder cancer by reducing evaluation of patients unlikely to have cancer or expediting identification of cancer. For surveillance, a marker trial could improve identification of bladder cancer or reduce cystoscopy in patients with low risk.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lotan Y, Black PC, Caba L, et al. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol. 2018. PMID: 31102625. doi:10.1016/j.euo.2018.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。